Last reviewed · How we verify
M-M-R®II
At a glance
| Generic name | M-M-R®II |
|---|---|
| Also known as | Measles, Mumps, and Rubella Virus Vaccine Live |
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
Common side effects
- Fever
- Rash
- Injection site reactions (pain, erythema, swelling, vesiculation)
- Headache
- Diarrhea
- Vomiting
- Nausea
- Measles-like rash
- Cough
- Sore throat
- Rhinitis
- Malaise
Serious adverse events
- Anaphylaxis
- Encephalitis
- Subacute sclerosing panencephalitis (SSPE)
- Guillain-Barré Syndrome (GBS)
- Stevens-Johnson syndrome
- Thrombocytopenia
- Pancreatitis
- Vasculitis
- Pneumonia
- Henoch-Schönlein purpura
Key clinical trials
- Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PHASE3)
- Characterization of New Phenotypes of Patients With Spinal Muscular Atrophy Treated With SMN Restoring Therapy (NA)
- Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL) (PHASE2)
- Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma (PHASE2)
- Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants (PHASE2)
- Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503) (PHASE2)
- DEC-C and Thioguanine for R/R AML (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- M-M-R®II CI brief — competitive landscape report
- M-M-R®II updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI